A phase 2b clinical study in patients with NASH and stage 3 liver fibrosis treatment with pegbelfermin (BMS-986036)–a pegylated human FGF21 analogue–significantly reduced extent of hepatic steatosis and improved surrogate markers of NASH (FALCON1, ClinicalTrials.gov (accessed on 28 December 2021) Identifier NCT03486899) [229]. Here, FGF21 is linked to fatty liver disease.